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Poster Session-I 85patients with SD achieved a 40% (0–80) OR rate (p 5 .02) for
a 50% (19–80) OS probability at 2 years (p 5 .001). Of the 4 pa-
tients in response at time of transplant, 3 increased their response
(PR 5 2; CR 5 1) and 3 were alive after 2 years. This study shows
that RIC-ASCT can be safely performed in BrC pts without
high transplant related mortality. However we show evidences
that pts with highly progressive disease do not benefit from this ap-
proach. In contrast, a high rate of response associated with pro-
longed survival can be achieved in patients with slowly
progressive disease. Better results could perhaps be achieved only
in pts in the initial disease phase when treatment disease resistance
has not occurred.233
INCREASED FREQUENCY AND RESPONSIVENESS OF PSA-SPECIFIC T
CELLS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR PROS-
TATE CANCER
Mattsson, J., Okas, M., Ringden, O., Uhlin, M. Clinical Immunology,
Stockholm, Sweden
Therapies for localized prostate cancer include curative surgery
and radiotherapy while treatment of metastatic disease is often in-
sufficient. Therefore, we started to investigate the potential of allo-
geneic SCT as a treatment for non-curable prostate cancer. A
patient underwent allogeneic SCT from his HLA-identical sister
after a non-myeloablative conditioning regimen as treatment for
his metastatic prostate adenocarcinoma. The patient was treated
with donor lymphocyte infusions after SCT due to threatening re-
jection. Frequencies of prostate-specific T cells in the peripheral
blood of the patient, sibling donor and a group of control individ-
uals were determined by flow cytometry using tetrameric and pen-
tameric HLA A2 complexes containing peptides derived from the
prostate specific antigen (PSA). Cytotoxic activity of PSA-
peptide-specific T-cells against peptide-pulsed target cells was
analyzed ex vivo by 51Cr-release assays. Stable clinical and labora-
tory remission lasting for more than 5 years was observed after
SCT. Using HLA containing pentamers with PSA-derived pep-
tides we could detect prostate-specific CD81 T cells in this patient
in high frequencies over several months. Furthermore, higher fre-
quencies of PSA-specific T-cells were revealed in the peripheral
blood of the patient and female controls as compared with male
healthy controls. Recently the PSA levels in the patient started to
increase and prostate biopsies showed prostate carcinoma in 3/8 bi-
opsies, Gleason 414, totally 3.5 mm of cancer (of 100 mm totally).
Due to this progression we have initiated a protocol for adoptive
transfer of allogeneic PSA-specific T cells from the patient. We
will, by using pentamers and flourocrome specific beads separate
out PSA specific T cells from the patient. In order to break a possi-
ble tolerance we will keep them in high concentration of IL-2
and the respective peptides in vitro culture over night before injec-
tion back into the patient. Clinical data of this novel therapy will
be presented at the meeting.Our data suggest that allogeneic
SCT led to the generation of a T cell mediated prostate-specific
immunity in the reported patient. The in vitro and ex vivo immuno-
logical monitoring performed indicate an adjuvant anti-tumor
effect of PSA-specific T cells. This report presents a novel
treatment approach involving allogeneic SCT in prostate cancer
patients who do not respond to chemotherapy and/or cannot
undergo prostectomy.STEM CELL BIOLOGY
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COMPLETE LONG-TERM HEMATOPOIETIC ENGRAFTMENT BY LINEAGE-
DEPLETED ALDH CD341 UCB CELLS
Liu, C.1, DeOliveira, D.1, Sempowski, G.D.2, Chao, N.J.1, Chen, B.J.1,
Storms, R.W.1 1Duke University Medical Center, Durham, NC;
2Duke University Medical Center, Durham, NC
In previous work, we fractionated CD341 umbilical cord blood
(UCB) progenitors to purify cells that express high levels of aldehydedehydrogenase (ALDH). The ALDHbr CD341 cells were enriched
with progenitors that engraft NOD/SCID mice in both short-term
(6–8 week) and long-term (.18 week) transplants. In contrast,
ALDHneg CD341 progenitors were not a significant source of
NOD/SCID repopulating cells. These data strongly imply that
transplantable human progenitors express ALDH; however, one
shortcoming for that work remains that human hematopoietic devel-
opment in NOD/SCID mice is limited to the myeloid and B-lym-
phoid lineages. Because the pace of T cell engraftment is a critical
clinical concern, we have adopted the use of the NOD/SCID-
IL2Rgnull mouse xenograft transplant model. In the current study,
20 mice were transplanted with lineage-depleted ALDHbr CD341
progenitors at doses that ranged from 3,000 to 30,000 cells. In con-
trol studies, similar doses of ALDHneg CD341 cells did not provide
long-term engraftment. So that we might characterize the behavior
of individual UCB, each transplant graft was derived from a single
UCB. In addition, each UCB was assayed in multiple different
mice. Twelve of 13 mice that survived until 21 weeks post-transplant
demonstrated multiple-lineage human hematopoietic engraftment.
Human T, B, NK and myeloid cells were detected in the bone mar-
row and spleen. In addition, in 9 mice human T cells were detected in
the thymus. Furthermore, 7 mice had sufficient thymus tissue to
measure T cell Receptor Excision Circles (TREC). By that assay, 3
of those mice demonstrated active human T cell rearrangements.
As anticipated, the level of engraftment to all tissues was cell
dose-dependent. One strength for this xenograft model was that
engraftment could be monitored over time within the peripheral
blood. Human B cells engrafted within 7 weeks post-transplant
and were detected in 17 of 19 mice ($ 5 B cells/mL). At 16 weeks
post-transplant, 15 of 18 mice maintained detectable B cells. In
contrast, human T cells emerged later, beginning at 13 weeks
post-transplant. However, even by 16 weeks post-transplant, T cells
were only detectable in the peripheral blood of 6 of 18 mice ($ 5 T
cells/mL). These studies provided evidence that ALDHbr CD341
cells establish both short- and long-term hematopoiesis in NOD/
SCID-IL2Rgnull mice. The emergence of T cells was the most
stringent test for long-term engraftment.235
HUMAN EMBRYONIC STEM CELLS-DERIVED HEMANGIOBLAST EXPRESS
HLA-ANTIGENS
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The initial differentiation of vascular endothelium and hemato-
poietic cells during embryogenesis occurs in the mesodermal layer
of the yolk sac, yielding structures called blood islands. We hypoth-
esized that under specific conditions this process can be recapitulated
in embryoid body (EB)-derived cell cultures and that such cells will
be able to form colonies of functional cells with dual hematopoietic/
endothelial potential. We used two-step differentiation technology
to obtain the bipotential blast cells from human embryonic stem cells
(hES). This involved short differentiation in our EB system followed
by differentiation in semisolid culture media supplemented with
mixture of cytokines. We have shown that the occurrence of heman-
gioblast (blast colony-forming cells) – BL-CFC during EB differen-
tiation (day 0–6) is transient and peaks on day 3. The emergence of
this event was associated with expression of T (early mesoderm
gene), and was suppressed by the development of endoderm layer.
Similarly, the highest BL-CFC count was associated with dramatic
increase in early hematopoietic/endothelial genes: CD34, CD31
and KDR. The similar pattern of expression of Patch1 and Gli1
genes suggested association with hedgehog (Hh) pathway. BL-
CFC colonies were composed of 30–50 blast cells on day 6. These
cells had homogenous morphology in Wright-Giemsa stain with
a big nucleus containing disorganized chromatin and a narrow rim
of cytoplasm filled with large-size granules. As shown by FACS stain-
ing, they were heterogenous and expressed markers of early hemato-
poietic and endothelial cells (CD31, CD34, VE-cadherin, Flt-1) and
mature differentiated cells (CD45, CD33, CD146). Some of them
expressed fetal and embryonic globin genes as shown RT-PCR.
Moreover, they could be characterized by higher expression of
HLA class I molecules when compared to hES and EB cells.
